![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
Patients Switching From a Calcium-Based Binder: When patients are converting from a calcium based phosphate binder, Sevelamer hydrochloride should be given in equivalent doses on a mg for mg weight basis compared to the patient's previous calcium based phosphate binder. Table 2 gives recommended starting doses of Sevelamer Carbonate based on a patient's current calcium acetate dose. (See Table 2.)
![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
Dose Titration for All Patients Taking Sevelamer Carbonate: Serum phosphorus levels should be closely monitored and the dose of Sevelamer Carbonate adjusted accordingly with the goal of lowering serum phosphorus to 1.78 mmol/L (5.5 mg/dL) or less. Serum phosphorus should be tested every 2 to 3 weeks until a stable serum phosphorus level is reached, and on a regular basis thereafter.
Special Populations: Use in Children: The safety and efficacy of Sevelamer Carbonate has not been established in patients below the age of 18 years.
Use in the Elderly: Same as adults.
Administration: Route of administration is oral.
Sevelamer Carbonate 800 mg tablets can be taken three times per day with meals at a dosage based on individual patient requirements to control phosphate levels. Tablets should be swallowed intact and should not be crushed, chewed, or broken into pieces prior to administration.